Physician profile
David M Lowry
NPI 1528033552
$3,451.19
in general payments reported to CMS, 2019-2025
25 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,583 · 2020: $542 · 2021: $314 · 2022: $550 · 2023: $128 · 2024: $121 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,001.63 | 2019-2022 | |
| Medtronic, INC. | $399.27 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $176.86 | 2019-2024 | Xiaflex |
| Pacira Therapeutics, INC. | $160.62 | 2019-2021 | |
| Innovation Technologies INC | $113.76 | 2025 | Irrisept |
| Heron Therapeutics, INC. | $89.63 | 2021-2022 | |
| Nalu Medical, INC. | $73.58 | 2024 | Nalu Neurostimulation System |
| Djo, LLC | $69.53 | 2023-2025 | Cmf |
| Horizon Therapeutics Plc | $48.57 | 2019-2021 | |
| Endo USA, INC. | $35.31 | 2025 | Xiaflex |
| Kowa Pharmaceuticals America, INC. | $33.92 | 2022-2023 | Seglentis |
| Linvatec Corporation | $28.83 | 2022-2023 | Biobrace 23mm |
| Depuy Synthes Sales INC. | $27.70 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $21.65 | 2023 | Iovera, Zilretta, Exparel |
| Ipsen Biopharmaceuticals, INC | $19.34 | 2023 | Dysport |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.57 | 2019 | |
| Abbott Laboratories | $17.01 | 2022 | |
| Vericel Corporation | $16.94 | 2022 | |
| Saluda Medical Americas, INC. | $15.29 | 2025 | Evoke |
| Abbvie INC. | $15.20 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.06 | 2024 | Strensiq |
| Fidia Pharma USA INC. | $14.68 | 2022 | |
| Smith+Nephew, INC. | $14.33 | 2021 | |
| Ibsa Pharma INC. | $14.20 | 2024 | Licart, Tirosint |
| Ultragenyx Pharmaceutical INC. | $9.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.